Search results
Results From The WOW.Com Content Network
The United States Drug Enforcement Administration (DEA) maintains lists regarding the classification of illicit drugs (see DEA Schedules). It also maintains List I of chemicals and List II of chemicals, which contain chemicals that are used to manufacture the controlled substances/illicit drugs. The list is designated within the Controlled ...
The drug or other substance has a high potential for abuse. The drug or other substance has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use of the drug or other substance under medical supervision. The complete list of Schedule I substances is as follows. [1]
Any antiretroviral drug: Black tar heroin: Whoonga, Nyaope [8] Widespread use in South Africa. Whoonga is classically reputed to be a combination of heroin with antiretroviral drugs such as ritonavir and/or efavirenz, often combined with additional drugs such as cannabis or hashish, methamphetamine and/or methaqualone: Any deliriant or diphen ...
Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs , ranked by sales.
The Drug Enforcement Administration was established on July 1, 1973, [4] by Reorganization Plan No. 2 of 1973, signed by President Richard Nixon on July 28. [5] It proposed the creation of a single federal agency to enforce the federal drug laws as well as consolidate and coordinate the government's drug control activities.
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required, by section 202 of that Act, for substances to be placed in this schedule: The drug or other substance has a high potential for abuse.
The 15 drugs accounted for $41 billion, or 14%, of total Medicare Part D spending between Nov. 1, 2023, and Oct. 1, 2024.
Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies: Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis. Gemtuzumab ozogamicin: IV: CD33 antibody that induces apoptosis of the tagged cell. Acute myeloid leukaemia